Cyclarity Unveils Oxidized Cholesterol Excretion Data

Key Takeaways

• First human trial shows urinary excretion of 7‑ketocholesterol.
• No serious adverse events reported across all dose levels.
• Half‑life of UDP‑003 is approximately three hours.
• Dose‑dependent PK profile supports infrequent dosing.
• Phase 2 trial slated for late 2026 to assess plaque regression.

Pulse Analysis

Oxidized cholesterol, particularly 7‑ketocholesterol (7KC), is recognized as a primary driver of plaque formation, inflammation, and arterial instability. Traditional cardiovascular drugs—statins, anti‑inflammatories, and emerging RNA therapies—modulate systemic pathways but rarely eliminate the toxic molecules that seed atherosclerosis. By directly binding 7KC and escorting it to the kidneys for urinary excretion, Cyclarity’s approach attacks the disease at its source, offering a mechanistic shift from risk management to true plaque reversal. This strategy aligns with a growing consensus that removing the underlying toxin could dramatically lower heart‑attack and stroke incidence.

The Phase 1 trial at Monash Victorian Heart Institute delivered the first human proof‑of‑concept for this concept. Participants receiving UDP‑003 exhibited clear, dose‑dependent urinary clearance of 7KC, while safety data remained clean—no serious adverse events and a short three‑hour half‑life that limits systemic exposure. Pharmacokinetic analyses revealed a linear dose‑exposure relationship, supporting infrequent dosing schedules that could improve adherence compared with daily statins. The molecule was discovered using Cyclarity’s proprietary AI platform, which designs cyclodextrin scaffolds to capture hydrophobic toxins, illustrating the power of machine‑learning‑guided chemistry in drug development.

With the safety and pharmacodynamic milestones achieved, Cyclarity is enrolling acute coronary syndrome patients for a plaque‑imaging cohort and plans a Phase 2 trial in late 2026 to test plaque regression as a primary endpoint. If successful, UDP‑003 could open a new therapeutic class targeting oxidized lipids, extending beyond cardiovascular disease to conditions such as Alzheimer’s and NASH where 7KC also plays a pathogenic role. Investors and clinicians alike will watch closely, as a disease‑modifying, toxin‑removing drug could reshape the market for cardiovascular therapeutics and reinforce the commercial promise of AI‑driven biopharma pipelines.